ECC 0509
Alternative Names: ECC-0509Latest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator Eccogene
- Class Analgesics; Hepatoprotectants; Small molecules
- Mechanism of Action AOC3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Musculoskeletal pain; Non-alcoholic steatohepatitis
Most Recent Events
- 15 Nov 2024 Eccogene plans a phase II trial for Non-alcoholic steatohepatitis (PO, Capsule)
- 15 Nov 2024 Pharmacodynamics and adverse event data from phase I trial in Non-alcoholic steatohepatitis released by Eccogene
- 12 Nov 2021 Pharmacodynamics data from a preclinical trial in Non-alcoholic steatohepatitis presented at 72nd annual meeting of the American Association for the Study of Liver Diseases (AASLD-2021)